← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › PROTEIN KINASE INHIBITORS › Cellular-mesenchymal-epithelial transition factor (c-MET) kinase inhibitors
savolitinib
L01EP03
Forms & Strengths
- 25mg, 50mg capsules
- Oral administration
Adult Dosing
- 100-200mg daily, may be adjusted based on tolerance and efficacy
- Recommended dose: 100mg orally once daily for MET-positive advanced solid tumors
Pediatric Dosing
- Safety and efficacy not established in pediatric patients
- Not recommended for use in children and adolescents
Indications
- Treatment of adult patients with MET-positive advanced solid tumors
- Specifically, used for treatment of non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation
Mechanism of Action
- Selective inhibitor of the mesenchymal-epithelial transition (MET) tyrosine kinase
- Blocks MET signaling pathways, inhibiting tumor growth and proliferation
Contraindications
- Hypersensitivity to savolitinib or its components
- Not recommended in patients with severe hepatic impairment
Adverse Reactions
- Common: fatigue, nausea, vomiting, diarrhea, decreased appetite
- Serious: interstitial lung disease, elevated liver enzymes, QT interval prolongation
Drug Interactions
- Strong CYP3A4 inhibitors: may increase savolitinib plasma concentrations
- Strong CYP3A4 inducers: may decrease savolitinib plasma concentrations
- QT interval prolonging drugs: may increase risk of QT interval prolongation
Curated Content: Needs Vetting Before Put to Clinical Use